The approval has been welcomed by the ASI as a ‘significant step’ for early Alzheimer’s treatment, but adverse affects have been noted from the drug’s clinical trials.
Read more: US approves Alzheimer’s drug designed to slow cognitive decline
The approval has been welcomed by the ASI as a ‘significant step’ for early Alzheimer’s treatment, but adverse affects have been noted from the drug’s clinical trials.
Read more: US approves Alzheimer’s drug designed to slow cognitive decline
